Atopic dermatitis patient registry for medication safety and results
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study is a real-world registry that collects information from adults with atopic dermatitis (eczema) to track how newly started treatments work and how safe they are over time. It may help researchers and doctors better understand medication effects in everyday care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with atopic dermatitis (eczema) by a dermatologist or qualified skin specialist
- You are 18 years or older and able to legally consent to this study
- You are willing to sign consent and share needed personal information (like contact details)
- You are starting a new eczema medicine you have never taken before
- Your new medicine was started either at the time of enrollment or within the last 12 months
- You are not currently in—and don’t plan to join—a masked (blinded) eczema drug clinical trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This registry tracks the safety and effectiveness of medications used for moderate to severe atopic dermatitis (eczema) in adolescents aged 10 to 15. It helps doctors understand how well these treatments work and what side effects might occur over time.
This study is a long-term registry for adolescents and adults with atopic dermatitis (eczema) who are starting or switching to a systemic medication (a drug that works throughout the body). It will track how these treatments work in real life and how patients feel over time.
This study is a registry for people with eczema (atopic dermatitis) who are under 26 and have taken or plan to take body-wide treatments like pills or injections. By joining, you help researchers track how these treatments work over time.
This registry study collects questionnaire information from people with atopic dermatitis (eczema) who are starting newer whole-body (systemic) treatments. It may help doctors better understand how these new options work in everyday care.
This study follows adults with moderate to severe eczema who are eligible for or already taking systemic (pill or injection) medicines. It does not test any new drug—it simply tracks how eczema is managed in real life, which may help improve future care.
This registry tracks adults with moderate to severe atopic dermatitis (eczema) over time. It helps doctors learn more about the disease and how treatments work in real life.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.